Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Nov 18, 8:32 AMNo clear catalyst identified for Roivant’s 6.2% premarket drop; conference remarks were already public
Index
RUI
Market Cap
28.06B
Enterprise Value
24.54B
Income
-360.12M
Sales
41.08M
Book/sh
5.56
Cash/sh
5.81
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
721
IPO
Dec 08, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
683.11
P/B
6.97
P/C
6.67
P/FCF
-
EV/EBITDA
-
EV/Sales
597.29
Quick Ratio
15.56
Current Ratio
15.56
Debt/Eq
0.03
LT Debt/Eq
0.02
Option/Short
Yes / Yes
EPS (ttm)
-0.56
EPS next Y
-1.14
EPS next Q
-0.29
EPS this Y
-112.79%
EPS next Y
0.90%
EPS next 5Y
-0.21%
EPS past 3/5Y
32.67% 34.68%
Sales past 3/5Y
-48.73% -19.07%
EPS Y/Y TTM
9.46%
Sales Y/Y TTM
102.09%
EPS Q/Q
-72.11%
Sales Q/Q
2135.58%
Insider Own
27.42%
Insider Trans
-5.62%
Inst Own
80.04%
Inst Trans
4.22%
ROA
-7.17%
ROE
-8.59%
ROIC
-8.76%
Gross Margin
82.51%
Oper. Margin
-3233.98%
Profit Margin
-876.58%
SMA20
1.52%
SMA50
3.94%
SMA200
18.94%
Trades
Shs Outstand
723.69M
Shs Float
525.91M
52W High
42.50 -8.87%
52W Low
19.96 94.04%
Volatility
3.29% 4.06%
ATR (14)
1.50
RSI (14)
53.61
Beta
1.18
Rel Volume
0.00
Avg Volume
8.10M
Volume
0
Perf Week
-7.46%
Perf Month
10.91%
Perf Quarter
5.13%
Perf Half Y
19.50%
Perf YTD
78.48%
Perf Year
88.74%
Perf 3Y
331.77%
Perf 5Y
376.97%
Perf 10Y
-
Prev Close
38.73
Price
38.73
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$50.82
Implied Upside
+31.2%
Analysts16incl. previous ratings
Rating Distribution14 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 12, 2026Downgrade
WWolfe Research
Outperform → Peer Perform
Sep 17, 2026Initiated
SF logoSStifel
Buy$51+31.7%
Mar 20, 2026Initiated
BBernstein
Outperform$35-9.6%
Sep 02, 2025Initiated
C logoCCitigroup
Buy$16-58.7%
Jul 10, 2025Resumed
GS logoGGoldman
Buy$19-50.9%
Feb 15, 2024Initiated
WWolfe Research
Outperform$17-56.1%
Jan 05, 2024Initiated
PPiper Sandler
Overweight$20-48.4%
Dec 12, 2023Initiated
DB logoDDeutsche Bank
Buy$14-63.9%
Oct 17, 2023Initiated
GGuggenheim
Buy$17-56.1%
Jun 08, 2023Initiated
BAC logoBBofA Securities
Neutral$10.50-72.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MANCHESTER KEITH SDirectorNov 16 '26Sale39.14779,74130,515,455911,127Nov 18 06:08 PM
MANCHESTER KEITH SDirectorNov 17 '26Sale38.24602,02123,021,2830Nov 18 06:08 PM
Gold Daniel AllenDirectorNov 16 '26Sale39.14779,74130,515,455911,127Nov 18 06:04 PM
Gold Daniel AllenDirectorNov 17 '26Sale38.24602,02123,021,2830Nov 18 06:04 PM
QVT Financial LPDirector by DeputizationNov 16 '26Sale39.14779,74130,515,455911,127Nov 18 05:29 PM
QVT Financial LPDirector by DeputizationNov 17 '26Sale38.24602,02123,021,2830Nov 18 05:29 PM
Pulik RichardCFONov 11 '26Option Exercise3.85127,365490,355397,046Nov 12 07:01 PM
Pulik RichardCFONov 10 '26Option Exercise3.85125,000481,250394,681Nov 12 07:01 PM
Pulik RichardCFONov 11 '26Sale41.85175,0007,323,272222,046Nov 12 07:01 PM
Pulik RichardCFONov 10 '26Sale41.20125,0005,150,000269,681Nov 12 07:01 PM
Venker EricPresident & Immunovant CEONov 10 '26Sale40.53187,9437,617,074811,211Nov 12 07:00 PM
RICHARD PULIKOfficerNov 11 '26Proposed Sale41.85175,0007,323,568Nov 12 08:49 AM
Venker EricOfficerNov 10 '26Proposed Sale40.53187,9437,617,817Nov 10 04:36 PM
MAYUKH SUKHATMEOfficerNov 10 '26Proposed Sale41.00173,7257,122,725Nov 10 04:28 PM
MATTHEW ADAM GLINEOfficerNov 10 '26Proposed Sale41.00164,1366,729,576Nov 10 04:25 PM
FRANK M TORTIOfficerNov 10 '26Proposed Sale41.081,234,96450,732,321Nov 10 04:23 PM
RICHARD PULIKOfficerNov 10 '26Proposed Sale41.20125,0005,150,575Nov 10 04:23 PM
Venker EricPresident & Immunovant CEONov 03 '26Sale36.31200,0007,262,000999,154Nov 05 06:11 PM
Venker EricOfficerNov 03 '26Proposed Sale36.31200,0007,262,568Nov 03 04:29 PM
Venker EricPresident & Immunovant CEOOct 28 '26Sale36.59200,0007,318,0001,199,154Oct 30 06:29 PM
Venker EricOfficerOct 28 '26Proposed Sale36.59200,0007,317,764Oct 28 04:35 PM
Venker EricPresident & Immunovant CEOOct 20 '26Sale35.11200,0007,022,6681,399,154Oct 22 06:44 PM
Venker EricOfficerOct 20 '26Proposed Sale35.12200,0007,023,513Oct 20 04:44 PM
Epperly Melissa B,DirectorOct 01 '26Option Exercise4.4617,75079,16532,704Oct 05 06:05 PM
Epperly Melissa B,DirectorOct 01 '26Sale36.1017,750640,86114,954Oct 05 06:05 PM
Venker EricPresident & Immunovant CEOSep 30 '26Option Exercise3.85200,000770,0001,799,154Oct 02 05:37 PM
Venker EricPresident & Immunovant CEOSep 30 '26Sale36.62200,0007,324,0001,599,154Oct 02 05:37 PM
Venker EricOfficerSep 30 '26Proposed Sale36.62200,0007,323,556Sep 30 04:21 PM
Epperly Melissa B,DirectorSep 15 '26Sale39.744,938196,2309,900Sep 17 06:43 PM
Fitzgerald MeghanDirectorSep 15 '26Sale39.745,112203,15236,108Sep 17 06:42 PM
MELISSA EPPERLYDirectorSep 15 '26Proposed Sale41.0222,688930,662Sep 15 04:40 PM
MEGHAN FITZGERALD OfficerSep 15 '26Proposed Sale41.025,112209,694Sep 15 04:32 PM
Fitzgerald MeghanDirectorSep 08 '26Option Exercise8.8020,000176,00062,963Sep 10 09:00 PM
Fitzgerald MeghanDirectorSep 08 '26Sale39.9020,000798,00042,963Sep 10 09:00 PM
MEGHAN FITZGERALD DirectorSep 08 '26Proposed Sale34.9320,000698,600Sep 08 04:27 PM
Venker EricPresident & Immunovant CEOAug 28 '26Option Exercise3.85200,000770,0001,799,154Sep 01 09:00 PM
Venker EricPresident & Immunovant CEOAug 28 '26Sale35.77200,0007,153,3931,599,154Sep 01 09:00 PM
Venker EricOfficerAug 28 '26Proposed Sale35.74200,0007,147,088Aug 28 04:33 PM
Sukhatme MayukhPresident & CIOAug 19 '26Option Exercise3.85172,899665,66118,803,638Aug 21 09:00 PM
Sukhatme MayukhPresident & CIOAug 21 '26Option Exercise3.85144,756557,31118,775,495Aug 21 09:00 PM
Sukhatme MayukhPresident & CIOAug 20 '26Option Exercise3.8517,51967,44818,648,258Aug 21 09:00 PM
Sukhatme MayukhPresident & CIOAug 19 '26Sale37.17172,8996,426,65618,630,739Aug 21 09:00 PM
Sukhatme MayukhPresident & CIOAug 21 '26Sale36.48144,7565,280,69918,630,739Aug 21 09:00 PM
Sukhatme MayukhPresident & CIOAug 20 '26Sale37.3017,519653,45918,630,739Aug 21 09:00 PM
MAYUKH SUKHATMEOfficerAug 21 '26Proposed Sale36.48144,7565,280,004Aug 21 04:20 PM
MAYUKH SUKHATMEOfficerAug 20 '26Proposed Sale37.3017,519653,408Aug 20 04:34 PM
MAYUKH SUKHATMEOfficerAug 19 '26Proposed Sale37.17172,8996,426,357Aug 19 04:23 PM
Sukhatme MayukhPresident & CIOAug 17 '26Option Exercise3.85284,7071,096,12218,915,446Aug 18 09:00 PM
Sukhatme MayukhPresident & CIOAug 14 '26Option Exercise3.85243,177936,23118,873,916Aug 18 09:00 PM
Sukhatme MayukhPresident & CIOAug 18 '26Option Exercise3.85136,942527,22718,735,880Aug 18 09:00 PM
Sukhatme MayukhPresident & CIOAug 17 '26Sale36.25284,70710,320,62918,630,739Aug 18 09:00 PM
Sukhatme MayukhPresident & CIOAug 14 '26Sale36.23243,1778,810,30318,630,739Aug 18 09:00 PM
Sukhatme MayukhPresident & CIOAug 18 '26Sale36.73136,9425,029,47018,630,739Aug 18 09:00 PM
MAYUKH SUKHATMEOfficerAug 18 '26Proposed Sale36.73136,9425,029,209Aug 18 04:29 PM
MAYUKH SUKHATMEOfficerAug 17 '26Proposed Sale36.25284,70710,320,572Aug 17 04:40 PM
MAYUKH SUKHATMEOfficerAug 14 '26Proposed Sale36.23243,1778,809,768Aug 14 04:20 PM
Venker EricPresident & Immunovant CEOJul 27 '26Option Exercise3.85200,000770,0001,813,063Jul 29 09:00 PM
Venker EricPresident & Immunovant CEOJul 27 '26Sale34.95200,0006,990,0001,613,063Jul 29 09:00 PM
Venker EricOfficerJul 27 '26Proposed Sale34.95200,0006,989,924Jul 27 04:16 PM
Fitzgerald MeghanDirectorJun 30 '26Option Exercise8.8010,00088,00052,963Jul 02 07:03 PM
Fitzgerald MeghanDirectorJun 30 '26Sale34.9010,000349,00042,963Jul 02 07:03 PM
Epperly Melissa B,DirectorJun 29 '26Option Exercise4.4617,75079,16534,224Jul 01 06:34 PM
Epperly Melissa B,DirectorJun 29 '26Sale34.3817,750610,25216,474Jul 01 06:34 PM
MANCHESTER KEITH SDirectorJun 29 '26Sale34.55800,00027,642,00013,701,546Jun 30 08:38 PM
MANCHESTER KEITH SDirectorJun 26 '26Sale34.00625,78321,275,30914,501,546Jun 30 08:38 PM
MANCHESTER KEITH SDirectorJun 30 '26Sale35.45200,0007,090,0001,748,403Jun 30 08:38 PM
MANCHESTER KEITH SDirectorJun 30 '26Sale35.2812,380436,76613,689,166Jun 30 08:38 PM
Gold Daniel AllenDirectorJun 29 '26Sale34.55800,00027,642,00013,701,546Jun 30 08:30 PM
Gold Daniel AllenDirectorJun 26 '26Sale34.00625,78321,275,30914,501,546Jun 30 08:30 PM
Gold Daniel AllenDirectorJun 30 '26Sale35.2812,380436,76613,689,166Jun 30 08:30 PM
QVT Financial LPDirector by DeputizationJun 29 '26Sale34.55800,00027,642,00013,701,546Jun 30 07:59 PM
QVT Financial LPDirector by DeputizationJun 26 '26Sale34.00625,78321,275,30914,501,546Jun 30 07:59 PM
QVT Financial LPDirector by DeputizationJun 30 '26Sale35.2812,380436,76613,689,166Jun 30 07:59 PM
MEGHAN FITZGERALD DirectorJun 30 '26Proposed Sale34.7310,000347,300Jun 30 04:36 PM
KEITH S MANCHESTERDirectorJun 30 '26Proposed Sale35.45200,0007,090,280Jun 30 04:25 PM
MELISSA EPPERLYDirectorJun 29 '26Proposed Sale34.0717,750604,742Jun 29 04:40 PM
Venker EricPresident & Immunovant CEOJun 24 '26Option Exercise3.85200,000770,0001,813,063Jun 26 06:13 PM
Venker EricPresident & Immunovant CEOJun 24 '26Sale33.16200,0006,631,2681,613,063Jun 26 06:13 PM
MAYUKH SUKHATMEOfficerJun 26 '26Proposed Sale34.08500,00017,039,650Jun 26 04:10 PM
MAYUKH SUKHATMEOfficerJun 25 '26Proposed Sale34.13500,00017,066,500Jun 25 04:33 PM
Venker EricOfficerJun 24 '26Proposed Sale33.16200,0006,631,659Jun 24 04:01 PM
Venker EricPresident & Immunovant CEOMay 22 '26Option Exercise3.85200,000770,0001,813,063May 22 06:25 PM
Venker EricPresident & Immunovant CEOMay 22 '26Sale30.27200,0006,054,0001,613,063May 22 06:25 PM
Venker EricOfficerMay 22 '26Proposed Sale30.27200,0006,054,731May 22 04:00 PM
Venker EricPresident & Immunovant CEOApr 20 '26Option Exercise3.85200,000770,0001,847,546Apr 22 06:27 PM
Venker EricPresident & Immunovant CEOApr 20 '26Sale29.59200,0005,918,0001,647,546Apr 22 06:27 PM
Gline MatthewCEOApr 16 '26Sale29.16289,7748,449,81016,736,116Apr 20 06:27 PM
Venker EricOfficerApr 20 '26Proposed Sale29.59200,0005,917,135Apr 20 04:17 PM
Gline MatthewOfficerApr 16 '26Proposed Sale29.16289,7748,449,876Apr 16 04:33 PM
Humes JenniferChief Accounting OfficerApr 08 '26Sale28.3713,538384,07384,191Apr 10 06:00 PM
JENNIFER HUMESOfficerApr 08 '26Proposed Sale28.3713,538384,035Apr 08 04:07 PM
Fitzgerald MeghanDirectorMar 26 '26Option Exercise8.8070,000616,000112,963Mar 30 09:01 PM
Fitzgerald MeghanDirectorMar 26 '26Sale27.4570,0001,921,50042,963Mar 30 09:01 PM
MEGHAN FITZGERALDDirectorMar 26 '26Proposed Sale27.4570,0001,921,458Mar 26 04:14 PM
Venker EricPresident & Immunovant CEOMar 17 '26Option Exercise3.85200,000770,0001,847,546Mar 19 06:36 PM
Venker EricPresident & Immunovant CEOMar 17 '26Sale28.24200,0005,648,0001,647,546Mar 19 06:36 PM
Epperly Melissa B,DirectorMar 16 '26Sale28.6841,8611,200,57315,804Mar 18 06:23 PM
Venker EricOfficerMar 17 '26Proposed Sale28.24200,0005,648,836Mar 17 04:17 PM
MELISSA B EPPERLYDirectorMar 16 '26Proposed Sale28.6841,8611,200,498Mar 16 04:04 PM
Torti FrankPresident and Vant ChairFeb 19 '26Option Exercise3.851,400,0005,390,00015,136,547Feb 23 08:40 PM
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
CEO & DirectorMr. Matthew Gline
Pharm.D.Dr. Eric Venker M.D.
PresidentDr. Mayukh Sukhatme M.D.
M.D.Dr. Frank M. Torti M.B.A.
Chief Financial OfficerMr. Richard Pulik